Eagle Pharmaceuticals, Inc. (EGRX) Reaches $74.42 After 9.00% Up Move; Greenwood Gearhart Lifted Its Exxon Mobil (XOM) Holding

June 19, 2018 - By Winifred Garcia

Exxon Mobil Corporation (NYSE:XOM) Logo

Greenwood Gearhart Inc increased Exxon Mobil Corp (XOM) stake by 8.86% reported in 2018Q1 SEC filing. Greenwood Gearhart Inc acquired 8,270 shares as Exxon Mobil Corp (XOM)’s stock declined 0.16%. The Greenwood Gearhart Inc holds 101,582 shares with $7.58M value, up from 93,312 last quarter. Exxon Mobil Corp now has $341.67 billion valuation. The stock decreased 0.15% or $0.12 during the last trading session, reaching $80.7. About 3.58 million shares traded. Exxon Mobil Corporation (NYSE:XOM) has declined 3.72% since June 19, 2017 and is downtrending. It has underperformed by 16.29% the S&P500. Some Historical XOM News: ; 07/03/2018 – Exxon: Upstream Plans Involve Low-Cost-Of-Supply Investments in U.S. Tight Oil, Deepwater, LNG; 29/03/2018 – PETROBRAS, QPI AND EXXON WIN BLOCK IN CAMPOS BASIN IN BRAZIL OIL AUCTION; 09/05/2018 – EXXON BATON ROUGE LOUISIANA REFINERY PREPARING TO RESTART CRUDE UNIT; 29/03/2018 – PETROBRAS, STATOIL, EXXON WIN CAMPOS BLOCK FOR 2.1B REAIS; 29/03/2018 – EXXON CLIMATE CHANGE RETALIATION SUIT TOSSED OUT; 05/03/2018 – IEA Head Speaks at CERAWeek, Exxon Plant Shutdown: Energy Wrap; 15/03/2018 – INSIGHT-Weathering Trump’s skepticism, US officials still fighting global warming; 12/04/2018 – Output Resumes at Exxon’s Papua New Guinea LNG Operation After Quake; 17/04/2018 – LIBERIA TO PROBE EXXON OIL DEAL AFTER GLOBAL WITNESS REPORT; 15/03/2018 – ExxonMobil Senior Vice President Mark Albers to Retire

The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is a huge mover today! The stock increased 2.21% or $1.61 during the last trading session, reaching $74.42. About 237,403 shares traded or 2.98% up from the average. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 9.68% since June 19, 2017 and is downtrending. It has underperformed by 22.25% the S&P500. Some Historical EGRX News: ; 10/04/2018 – Eagle Pharma at Deutsche Bank Health Care Conference May 9; 07/05/2018 – Eagle Pharma Closes Above 200-Day Moving Average: Technicals; 10/05/2018 – Eagle Pharmaceuticals Cash and Cash Equivalents Were $95.7M at March 3; 16/04/2018 – EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA; 01/05/2018 – Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018; 08/05/2018 – Eagle Pharma at Deutsche Bank Health Care Conference Tomorrow; 16/04/2018 – EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA OK’D FOR FILING BY FDA; 16/05/2018 – EAGLE PHARMACEUTICALS INC – EAGLE TO SHIP 500ML ADMIXTURE PRODUCT IMMEDIATELY; 16/05/2018 – Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml; 10/05/2018 – Eagle Pharmaceuticals Backs FY18 R&D Expense of $46M-$50M, SG&A Expense of $61M-$64MThe move comes after 9 months positive chart setup for the $1.10 billion company. It was reported on Jun, 19 by Barchart.com. We have $81.12 PT which if reached, will make NASDAQ:EGRX worth $99.36 million more.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on August, 8. They expect $0.85 earnings per share, up 157.58% or $0.52 from last year’s $0.33 per share. EGRX’s profit will be $12.61 million for 21.89 P/E if the $0.85 EPS becomes a reality. After $0.17 actual earnings per share reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 400.00% EPS growth.

More notable recent Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 11, 2018, also Streetinsider.com with their article: “Eagle Pharmaceuticals (EGRX) Confirms Court Issued Decision in Favor of it Granting Seven Year Orphan Drug …” published on June 11, 2018, Benzinga.com published: “Benzinga Pro’s 5 Stocks To Watch Today” on June 11, 2018. More interesting news about Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were released by: Businesswire.com and their article: “Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June” published on May 29, 2018 as well as Businesswire.com‘s news article titled: “Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA …” with publication date: June 11, 2018.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $1.10 billion. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 36.95 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Among 5 analysts covering Eagle Pharma (NASDAQ:EGRX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Eagle Pharma had 28 analyst reports since July 29, 2015 according to SRatingsIntel. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Wednesday, October 26 with “Buy” rating. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 25 report. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Monday, May 7 with “Sell” rating. The firm has “Underperform” rating by Mizuho given on Monday, January 9. The rating was maintained by RBC Capital Markets with “Buy” on Friday, July 14. Mizuho maintained the shares of EGRX in report on Friday, February 26 with “Buy” rating. The rating was maintained by RBC Capital Markets with “Buy” on Sunday, November 5. As per Wednesday, August 9, the company rating was maintained by Piper Jaffray. As per Wednesday, August 9, the company rating was maintained by Mizuho. The firm has “Sell” rating given on Thursday, May 17 by Mizuho.

Among 27 analysts covering Exxon Mobil (NYSE:XOM), 11 have Buy rating, 5 Sell and 11 Hold. Therefore 41% are positive. Exxon Mobil had 97 analyst reports since July 22, 2015 according to SRatingsIntel. The firm earned “Conviction Buy” rating on Friday, March 18 by Goldman Sachs. The firm has “Hold” rating by BMO Capital Markets given on Wednesday, January 10. The firm has “Long-Term Buy” rating by Hilliard Lyons given on Wednesday, June 7. The stock of Exxon Mobil Corporation (NYSE:XOM) has “Sell” rating given on Thursday, January 19 by UBS. The company was maintained on Monday, June 26 by BMO Capital Markets. Bank of America maintained Exxon Mobil Corporation (NYSE:XOM) on Thursday, March 8 with “Buy” rating. The stock of Exxon Mobil Corporation (NYSE:XOM) has “Sell” rating given on Tuesday, January 26 by Tudor Pickering. The stock of Exxon Mobil Corporation (NYSE:XOM) has “Buy” rating given on Friday, July 28 by Cowen & Co. The stock of Exxon Mobil Corporation (NYSE:XOM) earned “Hold” rating by Jefferies on Tuesday, October 3. On Wednesday, March 8 the stock rating was maintained by HSBC with “Hold”.

Exxon Mobil Corporation (NYSE:XOM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.